Phospho-CRKL (Y207) Antibody

說明書

中文名稱：

磷酸化-CRKL (Y207)兔多克隆抗體
貨號：

CSB-PA000736
規格：

￥1090
圖片：
Western Blot analysis of COS7 cells using Phospho-Crk-L (Y207) Polyclonal Antibody
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P46109
基因名：

CRKL
別名：

Crk L antibody; Crk like protein antibody; Crk-like protein antibody; Crkl antibody; CRKL_HUMAN antibody; Crkol antibody; HGNC:2363 antibody; Oncogene CrkL antibody; V crk avian sarcoma virus CT10 oncogene homolog like antibody; v crk sarcoma virus CT10 oncogene homolog (avian) like antibody; V crk sarcoma virus CT10 oncogene homolog avian like antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat,Monkey
免疫原：

Synthesized peptide derived from Human Crk-L around the phosphorylation site of Y207.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, IHC, IF, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:100-1:300
IF	1:200-1:1000
ELISA	1:5000

Protocols：

Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

May mediate the transduction of intracellular signals.
基因功能參考文獻：
1. Taken together, our data demonstrated that miR-429 might function as an antimetastatic miRNA to regulate HCC metastasis by directly targeting CRKL via modulating Raf/MEK/ERK-epithelial mesenchymal transition pathway. PMID: 29403024
2. High CRKL expression is associated with Cervical Cancer. PMID: 29295725
3. Silencing CRKL expression in PTEN-null human cancer cells leads to a decrease in p110beta-dependent PI3K signaling and cell proliferation. PMID: 28723560
4. Study found the expression of CRKL up-regulated and correlated with that of ABCG2 in gastric neoplasm. CRKL is one of the downstream molecules regulated by ABCG2, which promotes cell growth. PMID: 28029654
5. We demonstrated that CRKL is a novel downstream effector of ALK signaling in non-small-cell lung cancer PMID: 27078848
6. Dynamic multi-site phosphorylation by Fyn and Abl drives the interaction between CRKL and the novel scaffolding receptors DCBLD1 and DCBLD2. PMID: 29025973
7. Data show that miR-193b, by directly targeting focal adhesion kinase (FAK), CRK-like proto-oncogene (CRKL), and methionine sulfoxide reductase A (MSRA), regulates focal adhesion signaling and ROS signaling, which play pivotal roles in liposarcomagenesis and adipogenic differentiation. PMID: 28882999
8. TP53-miR-215-PCAT-1-CRKL axis might represent an important regulatory pathway in hepatocellular carcinoma. PMID: 28887306
9. The impaired T-cell proliferation and reduction of CRKL, phosphorylated CRKL, and c-Fos levels suggest a possible role of CRKL in functional deficiencies of T cells in patients with pDGS. PMID: 26875746
10. he findings in this study indicate a regulation relationship between CRKL and SLC7A5, and provide useful evidence for gastric cancer therapeutic strategies. PMID: 27846244
11. We identified a recurrent 370-kb deletion at the 22q11.2 locus as a driver of kidney defects in the DiGeorge syndrome and in sporadic congenital kidney and urinary tract anomalies. SNAP29, AIFM3, and CRKL appear to be critical to the phenotype, with haploinsufficiency of CRKL emerging as the main genetic driver. PMID: 28121514
12. a role for miR-429 as a novel target suppressing invasion and migration of human cervical cancer cells through modulation of its targeting genes ZEB1 and CRKL, is reported. PMID: 27133071
13. CrkL mediates CCL20/CCR6-induced epithelial-to-mesenchymal transition via Akt pathway, instead of Erk1/2 pathway in development of gastric cancer PMID: 26044596
14. CrkL regulates CCL19 and CCR7-induced epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinoma patients. PMID: 25636509
15. these results suggest that CrkL plays a regulatory role in the SDF-1-induced Erk1/2 and PI3K/Akt pathways and further managed the invasion and migration of breast cancer cells PMID: 25476480
16. The authors show that this potentiation involves reorganization of the natural CrkL-p85beta complex into a novel trimeric complex where influenza A virus NS1 serves as a bridging factor. PMID: 26099693
17. Our results demonstrate that the p53 target miR-200b/200c/429 miRNAs are negative regulators of the CRKL oncogene PMID: 26079153
18. results suggested that overexpression of CRKL promoted cell invasion through upregulation of MMP9 expression and activation of ERK pathway PMID: 24664993
19. CRKL has the potential to be used as a biomarker for the diagnosis, treatment and prognosis of certain tumors PMID: 25531052
20. We identified ZEB1 and CRKL as potential targets of miR-429 by analyzing combined results from in silico search and global expression array of the same RNA samples. Immunoblot assay confirmed that miR-429 reduced their expression at protein level. PMID: 25405387
21. These results indicate that CRKL gene amplification is rare in acquisition of resistance to EGFR-TKIs in lung cancer patients with EGFR mutations. PMID: 24939008
22. CrkL knockdown markedly suppressed the phosphorylated ERK (p-ERK) as well as the phosphorylated AKT (p-AKT) (p < 0.001) compared with control or TGF-b1 alone. PMID: 25307974
23. our study demonstrated that CRKL was overexpressed in human pancreatic cancers and contributed to pancreatic cancer cell proliferation and invasion through ERK signaling. PMID: 25318601
24. Study revealed that LASP1 phosphorylation results in an association with CRKL - another specific BCR-ABL substrate and bona fide biomarker for BCR-ABL activity. PMID: 24913448
25. Haploinsufficiency of CRKL could be responsible for the etiology of conotruncal heart defects in individuals with nested distal deletions and might act as a genetic modifier of individuals with the typical 3 Mb deletion. PMID: 25658046
26. CrkL is highly expressed in papillary thyroid carcinoma and papillary thyroid microcarcinoma and closely correlated to metastasis. PMID: 25185652
27. results suggest that CRKL has the ability to regulate colon cancer malignancy and CRKL has the potential to serve as a diagnosis and prognosis marker and a therapy target of colon cancer PMID: 24389200
28. CRKL is overexpressed in bladder cancer and regulates malignant cell growth and invasion. PMID: 24375195
29. This is the first report to elucidate the novel function of NS1--binding protein collaborating with viral protein NS1 in modulation of host cell physiology. In addition, an alternative role of adaptor protein CRKL in association with NS1 and NS1-BP during influenza A virus infection is demonstrated. PMID: 24220336
30. Data show Src-inducible association of CrkL with procaspase-8 promotes cell migration. PMID: 23751956
31. CRKL may recruit NleH1 to a host kinase on which NleH1 performs its inhibitory function. PMID: 24145029
32. we identified CRKL/YES as critical interrelated pathways necessary for rhabdomyosarcoma cell growth and survival and suggest a potential therapeutic role of SRC family kinase inhibition in the treatment of rhabdomyosarcoma. PMID: 23318429
33. Knock-down of CRKL in SGC-7901 cells induced a suppression of cell proliferation along with a significant arrest of cell cycle in G0/G1 phase. PMID: 24055140
34. Overexpression of CRKL in HBE and H1299 cell lines promoted cell proliferation by facilitating cell cycle progression. PMID: 22753141
35. High expression levels of the CRKL and CRKL-FLT1 pair strongly correlate with reduced disease-free and overall survival in HCC patient samples. PMID: 23397142
36. Overexpression of CRKL correlated with progression and malignant proliferation of human breast cancers. PMID: 23686806
37. SFK activity was shown to be sufficient, but not required for the interaction between ESDN and the CrkL-SH2 domain PMID: 23770091
38. study reveals a significant association between Crk protein expression with highly proliferative tumors and basal breast cancers of poor outcome; data highlight the physiological importance of Crk proteins in regulating growth of aggressive basal breast cancer cells PMID: 22569336
39. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response PMID: 22233112
40. Stathmin and CrkL proteins may be involved in drug resistance of K562 cells to adriamycin. PMID: 22169288
41. CRKL overexpression induces cell transformation. PMID: 22586683
42. These results suggested that CRKL protein is overexpressed in a subset of gastric cancers and is associated with CRKL amplification in gastric cancer. PMID: 22591714
43. In silico three-dimensional modeling of apoptin, molecular docking experiments between apoptin model and the known structure of Bcr-Abl, and the 3D structures of SH2 domains of CrkL and Bcr-Abl, were performed. PMID: 22253690
44. these results indicate that CRKL regulates HNSCC-cell growth, motility, and integrin-dependent cell adhesion, suggesting that CRKL plays a principal role in HNSCC tumorigenicity. PMID: 22244889
45. The molecular signaling set off by ERalpha and CrkL association may have a central role in pregnancy and cancer. PMID: 21700719
46. Lyn controls spatial activation of Rap1 by recruiting the CrkL-C3G protein complex to the leading edge PMID: 21628423
47. These results suggest that CRKL, but not MAPK1 is the target oncogene of the rare but recurrent amplification at 22q11.2 in laryngeal squamous cell carcinoma. PMID: 21896986
48. Findings indicate that amplification and resultant overexpression of CRKL contribute to diverse oncogenic phenotypes in lung cancer. PMID: 19966867
49. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines PMID: 12393632
50. directs ASAP1 to peripheral focal adhesions in platelets PMID: 12522101
顯示更多

收起更多
蛋白家族：

CRK family
數據庫鏈接：

HGNC: 2363

OMIM: 602007

KEGG: hsa:1399

STRING: 9606.ENSP00000346300

UniGene: Hs.5613

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human